A global resource to translational medicine: the International Park of Translational Medicine and BioMedicine (IPTBM)
1 Department of Respiratory Medicine, Fudan University, Shanghai, China
2 Section of Infectious Disease and Immunogenetics, Department of Transfusion Medicine, Clinical Center, National Institutes of Heath, Bethesda, MD, USA
3 Biomedical research Center, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
4 IPQ Analytics, LLC, Bethesda, MD, USA
5 Strategic Medicine, Inc, Bethesda, MD, USA
Journal of Translational Medicine 2013, 11:8 doi:10.1186/1479-5876-11-8Published: 8 January 2013
Translational science consists of research and development that integrates multiple resources to expedite the successful treatment of disease. The International Park of Translational BioMedicine (IPTBM) is currently being developed within the interface between Zhejiang Province and Shanghai Municipality. IPTBM has been designed to pioneer comprehensive biomedical research that spans the continuum from the education of young scientists to providing the infrastructure necessary for clinical testing and direct observation to better understand human biology while promoting viable commercial results within a vibrant biotechnology community. IPTBM’s goal is to attract global partners organized around five fundamental pillars: 1) Institutional Development, 2) Project Implementation, 3) Development and Production, 4) Investment and 5) Regulatory Clusters to address the needs of an international platform of scientists, institutes, universities, commercial enterprises, investors, politicians, and other stakeholders. The IPTBM differs from existing models including CTSA’s (US, NIH) technology because of its comprehensive approach to merge education, research, innovation, and development to translate clinical and public health needs into target-oriented and cost-efficient projects.